2.26
+0.02(+0.89%)
Currency In USD
| Previous Close | 2.24 |
| Open | 2.18 |
| Day High | 2.3 |
| Day Low | 2.13 |
| 52-Week High | 4.22 |
| 52-Week Low | 0.61 |
| Volume | 315,589 |
| Average Volume | 1.5M |
| Market Cap | 124.72M |
| PE | -1.54 |
| EPS | -1.47 |
| Moving Average 50 Days | 1.94 |
| Moving Average 200 Days | 1.25 |
| Change | 0.02 |
If you invested $1000 in Prelude Therapeutics Incorporated (PRLD) since IPO date, it would be worth $86.26 as of January 15, 2026 at a share price of $2.26. Whereas If you bought $1000 worth of Prelude Therapeutics Incorporated (PRLD) shares 5 years ago, it would be worth $30.36 as of January 15, 2026 at a share price of $2.26.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
GlobeNewswire Inc.
Dec 06, 2025 4:00 PM GMT
First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms PRT12396 has completed GLP toxicology studies and is on track for IND filing in the first quarter 2026 First di
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Nov 12, 2025 12:01 PM GMT
Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 Lead candidate from oral KAT6A selective degrader program advancing with IND filing expected in mid-2026 Preclinical
Prelude Therapeutics Announces Strategic Business Update
GlobeNewswire Inc.
Nov 04, 2025 12:05 PM GMT
Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement with Incyte, as previously anno